RSS

multiple myeloma

Morphogenesis — Florida-based immunotherapy company — and the Cell and Gene Therapy Group at Karolinska Institutet (KI) in Sweden have announced a collaboration for the development of targeted immunotherapies to treat cancer. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

Marketing authorisation for Darzalex (daratumumab), from the Janssen Pharmaceutical Companies of Johnson & Johnson, to be used as a frontline treatment for newly diagnosed patients with multiple myeloma has been granted by the European Commission. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended broadening the existing marketing authorisation for Janssen’s Darzalex (daratumumab) as a frontline treatment. more

News

Biotechnology company, Genmab, has announced that the FDA has approved the use of DARZALEX (daratumumab) in combination with bortezomib, melphalan and prednisone (VMP) for the treatment of patients with newly diagnos more

News

The US FDA has granted 510(k) clearance for the Hydrashift 2/4 daratumumab assay from Sebia, which is intended for use with Hydragel IF for the qualitative detection of monoclonal proteins in human serum by immunofixation electrophoresis. more

Technology

The US Food and Drug Administration (FDA) has granted priority review to the supplemental biologics licence application (sBLA) for the use of daratumumab in front line multiple myeloma. more

News